Bio-Rad Laboratories Inc
$ 299.02
2.72%
17 Apr - close price
- Market Cap 8,074,254,000 USD
- Current Price $ 299.02
- High / Low $ 302.32 / 292.19
- Stock P/E 10.45
- Book Value 276.16
- EPS 28.62
- Next Earning Report 2026-05-07
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.02 %
- ROE 0.11 %
- 52 Week High 343.12
- 52 Week Low 211.43
About
Bio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets.
Analyst Target Price
$302.50
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-12 | 2025-10-30 | 2025-07-31 | 2025-05-01 | 2025-02-13 | 2024-10-30 | 2024-08-01 | 2024-05-07 | 2024-02-15 | 2023-10-26 | 2023-08-03 | 2023-05-04 |
| Reported EPS | 2.51 | 2.26 | 2.61 | 2.54 | 2.9 | 2.01 | 3.11 | 2.29 | 3.1 | 2.33 | 3 | 3.34 |
| Estimated EPS | 2.71 | 1.94 | 1.75 | 1.78 | 2.88 | 1.18 | 2.01 | 2.15 | 2.82 | 2.78 | 2.68 | 3.54 |
| Surprise | -0.2 | 0.32 | 0.86 | 0.76 | 0.02 | 0.83 | 1.1 | 0.14 | 0.28 | -0.45 | 0.32 | -0.2 |
| Surprise Percentage | -7.3801% | 16.4948% | 49.1429% | 42.6966% | 0.6944% | 70.339% | 54.7264% | 6.5116% | 9.9291% | -16.1871% | 11.9403% | -5.6497% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-07 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 2.77 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BIO
2026-04-08 18:10:57
This article analyzes Bio-rad Laboratories Inc. Class A (NYSE: BIO), indicating a neutral near-term sentiment amidst mid and long-term strength. It highlights a significant 41.8:1 risk-reward setup targeting a 12.0% gain versus 0.3% risk. The analysis also provides three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods, along with multi-timeframe signal analysis.
2026-04-01 11:00:00
Artisan Mid Cap Value Fund divested its position in Bio-Rad Laboratories (NYSE: BIO) during Q4 2025, according to its investor letter. While acknowledging Bio-Rad's business, the fund expressed concern over the CEO's capital allocation strategy, specifically regarding large M&A. The proceeds from the sale were used to purchase Revvity.
2026-03-28 17:00:00
This article from Stock Traders Daily discusses real-time trading signals for Bio-rad Laboratories Inc. Class A (NYSE: BIO). It highlights the stock's strong near-term sentiment while noting potential breakdowns and elevated downside risk. The analysis includes three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis for different horizons.
2026-03-17 15:39:52
This article analyzes Bio-Rad Laboratories Inc. (NYSE: BIO) with AI-generated trading strategies. It highlights weak near-term sentiment but strong long-term prospects, identifying key support and resistance levels. The analysis provides specific entry and exit points for position trading, momentum breakout, and risk hedging strategies, emphasizing disciplined, rules-based execution.
2026-03-06 13:44:00
This article analyzes Bio-rad Laboratories Inc. Class A (NYSE: BIO) with AI-generated signals and strategies. It identifies a near-term strong sentiment, mid-term neutrality, and long-term positive bias, noting a current breakdown with elevated downside risk. The report provides specific entry, target, and stop-loss levels for position trading, momentum breakout, and risk hedging strategies.
2026-02-27 14:52:13
Bio-Rad Laboratories (BIO) has experienced a significant share price slump over the past five years, prompting a re-evaluation of its valuation. Despite the historical decline, a Discounted Cash Flow (DCF) analysis suggests the stock is currently undervalued by 33.4%, with an intrinsic value of about $418.03 per share compared to its current trading price of around $278.44. Additionally, its P/E ratio of 9.89x is considerably lower than the Life Sciences industry average, further indicating it may be trading below its fair value.
